

# Janice Pogue

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10852260/publications.pdf>

Version: 2024-02-01

57  
papers

31,663  
citations

101535

36  
h-index

155644

55  
g-index

57  
all docs

57  
docs citations

57  
times ranked

23843  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors, Prognosis, and Management of New Clinically Important Atrial Fibrillation After Noncardiac Surgery: A Prospective Cohort Study. <i>Anesthesia and Analgesia</i> , 2017, 125, 162-169.	2.2	35
2	Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. <i>European Stroke Journal</i> , 2016, 1, 146-154.	5.5	83
3	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2009-2020.	27.0	526
4	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2021-2031.	27.0	641
5	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2032-2043.	27.0	299
6	A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1332-1339.	1.7	7
7	Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 244-253.	11.4	92
8	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2016, 18, 973-978.	1.7	19
9	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. <i>Canadian Journal of Cardiology</i> , 2016, 32, 311-318.	1.7	24
10	Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2015, 132, 796-803.	1.6	90
11	Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , 2015, 386, 1243-1253.	13.7	268
12	Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia. <i>Circulation</i> , 2015, 132, 2297-2304.	1.6	64
13	Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. <i>Kidney International</i> , 2015, 87, 784-791.	5.2	86
14	Clinician-trialist rounds: 23. When an RCT's Data Center Report drowns vital information in seas of data: Where's Waldo?. <i>Clinical Trials</i> , 2014, 11, 601-604.	1.6	2
15	Prospective long-term evaluation of Optim-insulated (Riata ST Optim and Durata) implantable cardioverter-defibrillator leads. <i>Heart Rhythm</i> , 2014, 11, 2156-2162.	0.7	28
16	Response to Letter Regarding Article, "Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study". <i>Circulation</i> , 2014, 130, e85.	1.6	3
17	Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. <i>European Heart Journal</i> , 2014, 35, 1743-1751.	2.2	23
18	Clinician-trialist rounds: 19. Faux pas or fraud? Identifying centers that have fabricated their data in your multi-center trial. <i>Clinical Trials</i> , 2014, 11, 128-130.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Prognostic Usefulness of Left Ventricular Hypertrophy by Electrocardiography in Patients With Atrial Fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). American Journal of Cardiology, 2014, 113, 669-675.	1.6	14
20	Clonidine in Patients Undergoing Noncardiac Surgery. New England Journal of Medicine, 2014, 370, 1504-1513.	27.0	285
21	The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. Journal of Clinical Epidemiology, 2014, 67, 622-628.	5.0	504
22	Statistical Approaches to Improving Trial Efficiency and Conduct. , 2014, , 71-84.		0
23	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation, 2013, 128, 237-243.	1.6	195
24	Causes of Death and Influencing Factors in Patients With Atrial Fibrillation. Circulation, 2013, 128, 2192-2201.	1.6	268
25	Direct-Acting Oral Anticoagulants. JAMA Neurology, 2013, 70, 1483-4.	9.0	6
26	Nitrous Oxide and Serious Morbidity and Mortality in the POISE Trial. Anesthesia and Analgesia, 2013, 116, 1034-1040.	2.2	36
27	Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine, 2012, 367, 319-328.	27.0	1,426
28	Designing and Analyzing Clinical Trials with Composite Outcomes: Consideration of Possible Treatment Differences between the Individual Outcomes. PLoS ONE, 2012, 7, e34785.	2.5	40
29	Characteristics and Short-Term Prognosis of Perioperative Myocardial Infarction in Patients Undergoing Noncardiac Surgery. Annals of Internal Medicine, 2011, 154, 523.	3.9	557
30	Testing for heterogeneity among the components of a binary composite outcome in a clinical trial. BMC Medical Research Methodology, 2010, 10, 49.	3.1	21
31	Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux: The FUTURA/OASIS-8 Randomized Trial. JAMA - Journal of the American Medical Association, 2010, 304, 1339-1349.	7.4	161
32	Dabigatran and Warfarin in Vitamin K Antagonistâ€“Naive and â€“Experienced Cohorts With Atrial Fibrillation. Circulation, 2010, 122, 2246-2253.	1.6	158
33	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. European Heart Journal, 2010, 31, 2133-2140.	2.2	35
34	Fondaparinux with Unfractionated heparin during Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): A randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with nonâ€“ST-segment elevation acute coronary syndromes initially treated with fondaparinux. American Heart Journal, 2010, 160, 1029-1034.e1.	2.7	19
35	Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet, The, 2010, 376, 975-983.	13.7	913
36	Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. Clinical Trials, 2009, 6, 239-251.	1.6	105

#	ARTICLE	IF	CITATIONS
37	The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2009, 6, 96-97.	3.3	14
38	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 361, 1139-1151.	27.0	9,839
39	Effect of Telmisartan on Renal Outcomes. <i>Annals of Internal Medicine</i> , 2009, 151, 1.	3.9	163
40	Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. <i>New England Journal of Medicine</i> , 2008, 358, 1547-1559.	27.0	3,155
41	Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE) Tj ETQq1 1 0.784314 rgBT /Overdo	13.7	1,984
42	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	13.7	1,442
43	Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. <i>Circulation</i> , 2008, 118, 2029-2037.	1.6	789
44	Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. <i>Lancet, The</i> , 2006, 368, 581-588.	13.7	456
45	Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2006, 354, 1464-1476.	27.0	1,104
46	Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. <i>New England Journal of Medicine</i> , 2006, 354, 1567-1577.	27.0	1,536
47	Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction—a meta-analysis. <i>European Journal of Heart Failure</i> , 2006, 8, 90-96.	7.1	24
48	Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes. <i>Circulation</i> , 2005, 112, 1339-1346.	1.6	172
49	Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE Study. <i>Kidney International</i> , 2004, 65, 1375-1380.	5.2	102
50	Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. <i>American Heart Journal</i> , 2004, 148, 52-61.	2.7	388
51	Cardiovascular Risk in Patients with Early Renal Insufficiency. <i>American Journal of Cardiovascular Drugs</i> , 2002, 2, 157-162.	2.2	29
52	Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. <i>Lancet, The</i> , 2002, 360, 1037-1043.	13.7	230
53	Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial. <i>Annals of Internal Medicine</i> , 2001, 134, 629.	3.9	1,243
54	Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril. <i>Circulation</i> , 2001, 104, 1615-1621.	1.6	502

#	ARTICLE	IF	CITATIONS
55	Stroke in Relation to Cardiac Procedures in Patients With Nonâ€‘ST-Elevation Acute Coronary Syndrome. Circulation, 2001, 104, 269-274.	1.6	58
56	Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet, The, 2000, 355, 1575-1581.	13.7	1,398
57	Weighted Multiple Testing Correction for Correlated Binary Endpoints. Communications in Statistics Part B: Simulation and Computation, 0, , 130102064240003.	1.2	0